MXCT - MaxCyte signs strategic platform with LG Chem

• MaxCyte ( NASDAQ: MXCT ) has announced the signing of a strategic platform license with LG Chem, aiming to create new value for its customers based on science.
• Under the terms, LG Chem obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform.
• In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.
• “This partnership represents our first SPL with a South Korean company and broadens our reach into Asia to provide advanced technologies that support the clinical and commercial development of engineered cell therapies, and ultimately change the lives of patients with cancer.” said Doug Doerfler, President and CEO of MaxCyte.

For further details see: